Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in Colorectal Mucinous Adenocarcinoma
NCT04446091Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in Colorectal mucinous adenocarcinoma (CMAC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Colorectal mucinous adenocarcinoma (CMAC)
Beyond the preview
Go deeper on NCT04446091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446091.